Avoiding dialysis in tumour lysis syndrome: Is urate oxidase effective? - A case report and review of literature

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 8, 2007, Pages 679-683

  Teo, Wan Yee ^a   Loh, Tsee Foong ^a   Tan, Ah Moy ^a  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Acute renal failure; Hyperuricemia; Recombinant urate oxidase; Renal insufficiency

Indexed keywords

ALLOPURINOL; DIURETIC AGENT; FUROSEMIDE; RASBURICASE; URATE OXIDASE;

ANAMNESIS; ARTICLE; BURKITT LYMPHOMA; CASE REPORT; CLINICAL FEATURE; DIALYSIS; HUMAN; KIDNEY DYSFUNCTION; MALE; MEDICAL RECORD REVIEW; REHYDRATION; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

EID: 34548505287     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. de Bont JM, Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids 2004;23:1431-40.
2. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546-54.
3. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol 2005;3:117-24.
4. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001;38:13-21.
5. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-54.
6. Pession A, Barbieri E. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol 2005;147:80-92.
7. Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, et al. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2006;46:439-45.
8. Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma 2002;3Suppl1:S26-S31.
9. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Des 2005;11:4177-85.
10. Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol 2005;147:69-79.
11. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003;3:225-32.
12. Wang LY, Shih LY, Chang H, Jou ST, Lin KH, Yeh TC, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006;115:35-8.
13. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-6.
14. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002;13:789-95.
15. Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003;60:2213-22.
16. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RA. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999;34:E20.
17. Hummel M, Buchheidt D, Reiter S, Bergmann J, Adam K, Hehlmann R. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005;75:518-21.
18. Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol 2005;147:47-60.
19. Macfarlane RJ, McCully BJ, Fernandez CV. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr Nephrol 2004;19:924-7.
20. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003;82:160-5.